Clinical trials · Ohio
Atopic Dermatitis clinical trials in Ohio
We’re tracking 14 recruiting atopic dermatitis studies with a site in Ohio — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Ohio
- NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Boardman, OhioAges 18 years+ - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Columbus, OhioAges 18–74 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Canal Winchester, OhioAges 2–11 - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Canton, OhioAges 18–75 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Columbus, OhioAges 18–75 - NCT05995964RecruitingPhase 2
Study of two new medicines for eczema
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Mayfield Heights, OhioAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Columbus, OhioAges 18–65 - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Fairborn, OhioAges 6 months–18 years - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
Cincinnati, OhioAges 6 years+ - NCT05492578Enrolling by invitationPhase 2/Phase 3
Long-term follow-up of amlitelimab for moderate to severe eczema
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Cincinnati, OhioAges 12 years+ - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Boardman, OhioAges 18–65 - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Dayton, OhioAges 12 years+ - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Marion, OhioAges 12 years+ - NCT06241118RecruitingPhase 3
New injection for eczema not helped by other advanced treatments
This study tests a new injection called amlitelimab for teens and adults with moderate-to-severe eczema that hasn't gotten better with other advanced treatments like biologics or JAK inhibitor pills. It's given along with steroid creams to see if it can improve symptoms.
Cincinnati, OhioAges 12 years+
Atopic Dermatitis trials by city in Ohio
Where these studies are running in Ohio
Institutions with a site for the recruiting atopic dermatitis studies listed above.
- Cincinnati Children's Hospital Medical Center · 3 studies
- Apex Clinical Research Center · 2 studies
- Inmagene Site 5 · 2 studies
- Inmagene Site 9 · 2 studies
- Wright State Physicians · 2 studies
- ClinOhio Research Services
- Dermatologists of Southwest Ohio
- Dermatology Associates of Mid-Ohio Site Number : 8400052
What taking part in a atopic dermatitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Atopic Dermatitis trials in other states
Common questions
- Are there atopic dermatitis clinical trials in Ohio?
- Yes. We're currently tracking 14 recruiting atopic dermatitis studies with a site in Ohio, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a atopic dermatitis study in Ohio?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Ohio to take part?
- Not necessarily. These studies have a site in Ohio, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New atopic dermatitis studies open in Ohio regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.